Sebastián Alexis Vishnopolska

Dr. Sebastián Alexis Vishnopolska

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 July 2018 in Molecular Genetics & Genomic Medicine
Verified
Journal Article
Open access
PDF file
SVSebastián Alexis Vishnopolska
Sebastián Alexis Vishnopolska
ATAdrián G. Turjanski
Adrián G. Turjanski
MPMariana Herrera Piñero
Mariana Herrera Piñero
BGBoris Groisman
Boris Groisman
RLRosa Liascovich
Rosa Liascovich
MMMarcelo A. Marti
Marcelo A. Marti
A historical summary of genetics and genomic medicine in Argentina. We go through the achievements and difficulties in the implementation of genetic and genomic services both in academia and health care.

1 February 2020 in Growth Hormone & IGF Research
Verified
Journal Article
Closed access
NSNora Sanguineti
Nora Sanguineti
DBDebora Braslavsky
Debora Braslavsky
PSPaula A. Scaglia
Paula A. Scaglia
AKAna Keselman
Ana Keselman
MBMaria G. Ballerini
Maria G. Ballerini
IBIgnacio Bergadá
Ignacio Bergadá

18 February 2021 in Ophthalmic Genetics
Verified
Journal Article
Closed access
RMRodrigo Mendez
Rodrigo Mendez
SISumaiya Iqbal
Sumaiya Iqbal
SVSebastián Alexis Vishnopolska
Sebastián Alexis Vishnopolska
CMCinthia Martinez
Cinthia Martinez
GDGlenda Dibner
Glenda Dibner
MMMarcelo A. Marti
Marcelo A. Marti
Background: Oculocutaneous albinism (OCA) is a Mendelian disorder characterized by hypopigmentation of the skin, hair, and eyes, hypoplastic fovea, and low vision, known to be caused by mutations in the Tyrosinase (TYR) gene. Among the known TYR variants, some reduce but do not completely eliminate tyrosinase activity, allowing residual production of melanin and resulting in a contradictory assignment as either pathogenic or benign, preventing a precise clinical diagnostic. Materials and Methods: In the present work, we performed Whole Exome Sequencing and subsequent Sanger sequencing in a young male clinically diagnosed with OCA. Results: Whole-exome sequencing analysis revealed the identification of two variants in trans in TYR. The first, corresponds to a known pathogenic variant G47D, while the second S192Y, was considered a polymorphism due to its relatively high frequency in the European population. Conclusion: The lack of other pathogenic variants in TYR, the reported reduced enzymatic activity (ca. 40% respect to wt) for S192Y, together with the structural in-silico analysis strongly suggest that both reported variants are jointly disease-causing and that S192Y should be considered as likely pathogenic, especially when it is found in trans with a null variant.

8 February 2021 in medRxiv
Verified
Preprint
Open access
PDF file
PGPeter Gergics
Peter Gergics
CSCathy Smith
Cathy Smith
HBHironori Bando
Hironori Bando
AJAlexander Augusto Lima Jorge
Alexander Augusto Lima Jorge
DRDenise Rockstroh-Lippold
Denise Rockstroh-Lippold
SCSally Camper
Sally Camper
Pituitary hormone deficiency occurs in ∼1:4,000 live births. Approximately 3% of the cases are due to mutations in the alpha isoform of POU1F1, a pituitary-specific transcriptional activator. We found four separate heterozygous missense variants in unrelated hypopituitarism patients that were predicted to affect a minor isoform, POU1F1 beta, which can act as a transcriptional repressor. These variants retain repressor activity, but they shift splicing to favor the expression of the beta isoform, resulting in dominant negative loss of function. Using a high throughput splicing reporter assay, we tested 1,080 single nucleotide variants in POU1F1 . We identified 113 splice disruptive variants, including 23 synonymous variants. We evaluated separate cohorts of hypopituitarism patients and found two different synonymous splice disruptive variants that co-segregate with hypopituitarism. This study underlines the importance of evaluating the impact of variants on splicing and provides a catalog for interpretation of variants of unknown significance in the POU1F1 gene.

6 March 2025 in Endocrinology
Verified
Journal Article
Closed access
AWAmanda Helen Winningham
Amanda Helen Winningham
EREve Camper Rhoads
Eve Camper Rhoads
MBMichelle Lynn Brinkmeier
Michelle Lynn Brinkmeier
SVSebastián Alexis Vishnopolska
Sebastián Alexis Vishnopolska
JKJacob Otto Kitzman
Jacob Otto Kitzman
MPMaría Inés Pérez-Millán
María Inés Pérez-Millán
Mutations in the pituitary-specific transcription factor PROP1 are the most common, known cause of hypopituitarism in humans. Prop1 is the first pituitary-specific gene in the hierarchy of transcription factors that regulate pituitary development. It is essential for regulating the transition of pituitary stem cells to hormone-producing cells in an epithelial to mesenchymal-like transition process. It is also critical for activation of the lineage specific transcription factor POU1F1 in early organogenesis. Prop1 deficient mice have pituitary dysmorphology and lack the cells that produce growth hormone (GH), thyroid stimulating hormone (TSH), and prolactin (PRL). Prop1 is expressed in stem cells postnatally, but it is not known whether postnatal expression is necessary for completion of pituitary gland growth or organ maintenance. We tested whether PROP1 has a role in postnatal pituitary development by generating a conditional allele and deleting a crucial exon after birth. We determined that postnatal expression of Prop1 is important for appropriate expansion of the POU1F1 lineage and for robust expression of TSH, GH, and PRL in the early postnatal period. However, by 2 weeks of age, compensatory proliferation of committed POU1F1-expressing cells, but not SOX2-expressing stem cells, have normalized pituitary function. Thus, PROP1 appears to be dispensable after birth in mice.

1 January 2026 in Human Mutation
Verified
Journal Article
Open access
SVSebastián Alexis Vishnopolska
Sebastián Alexis Vishnopolska
JLJames Liu
James Liu
MCMaria Andrea Camilletti
Maria Andrea Camilletti
JMJulian Martinez Mayer
Julian Martinez Mayer
LGLucia Iglesias Garcia
Lucia Iglesias Garcia
MPMaría Inés Pérez-Millán
María Inés Pérez-Millán
PNPLA6 is a conserved lysophospholipase essential for maintaining nervous system integrity. Biallelic mutations in PNPLA6 have been identified in individuals with a broad spectrum of disorders that can include ataxia, vision loss, and pituitary hormone deficiency. Here, we report the identification of novel compound heterozygous variants in PNPLA6 (p.T1115P and p.Pro1142_Ala1143ins14) in a 10‐year‐old girl with combined pituitary hormone deficiency, including growth hormone, thyroid‐stimulating hormone, and gonadotropins. She also has vision loss and neurodevelopmental delay. Functional validation demonstrates that both variants, a missense substitution affecting a highly conserved residue within the catalytic domain and an intronic variant generating a novel splice acceptor site, completely abolish NTE activity, establishing their pathogenicity. Little is known about the cause of hypopituitarism in individuals with PNPLA6 deficiency. Here, we report the cell‐type‐specific expression of PNPLA6 in mouse pituitary development and in adult animals. PNPLA6 is expressed broadly in SOX2+ stem cells within the pituitary primordium as early as e10.5, prior to lineage specification, suggesting a role in progenitor maintenance and early differentiation. In neonates and adults, expression predominates in the cells that produce growth hormone and pro‐opiomelanocortin. These findings suggest that PNPLA6 could influence pituitary development at early stages, as well as contribute to the altered function of hormone‐secreting cells.